Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Merrouche

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
British Journal of Cancer|June 1, 1994
Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinomaA Ravaud, S Négrier, L Cany, et al.
Cancer|January 15, 1998
Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimensI Ray-Coquard, P Biron, T Bachelot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1995
Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancerB Chevallier, P Chollet, Y Merrouche, et al.
European Journal of Cancer (Oxford, England : 1990)|May 10, 2008
Relationship between nutritional status and quality of life in patients with cancerA Nourissat, M P Vasson, Y Merrouche, et al.
British Journal of Cancer|May 1, 1992
Intravenous interleukin-2 in patients over 65 with metastatic renal carcinomaS Négrier, A Mercatello, M Bret, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility studyY Merrouche, J M Extra, D Abigerges, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|April 1, 1993
[Immunotherapy of metastatic kidney cancer]S Négrier, A Mercatello, B Coronel, et al.
Cancer Research|June 15, 1992
Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinomaJ Y Blay, S Negrier, V Combaret, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 20, 2007
Estimation of the risk for nutritional state degradation in patients with cancer: development of a screening tool based on results from a cross-sectional surveyA Nourissat, D Mille, G Delaroche, et al.
British Journal of Cancer|January 1, 1997
Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinomaC Bain, Y Merrouche, I Puisieux, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
British Journal of Cancer|June 1, 1994
Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinomaA Ravaud, S Négrier, L Cany, et al.
Cancer|January 15, 1998
Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimensI Ray-Coquard, P Biron, T Bachelot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1995
Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancerB Chevallier, P Chollet, Y Merrouche, et al.
European Journal of Cancer (Oxford, England : 1990)|May 10, 2008
Relationship between nutritional status and quality of life in patients with cancerA Nourissat, M P Vasson, Y Merrouche, et al.
British Journal of Cancer|May 1, 1992
Intravenous interleukin-2 in patients over 65 with metastatic renal carcinomaS Négrier, A Mercatello, M Bret, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility studyY Merrouche, J M Extra, D Abigerges, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|April 1, 1993
[Immunotherapy of metastatic kidney cancer]S Négrier, A Mercatello, B Coronel, et al.
Cancer Research|June 15, 1992
Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinomaJ Y Blay, S Negrier, V Combaret, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 20, 2007
Estimation of the risk for nutritional state degradation in patients with cancer: development of a screening tool based on results from a cross-sectional surveyA Nourissat, D Mille, G Delaroche, et al.
British Journal of Cancer|January 1, 1997
Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinomaC Bain, Y Merrouche, I Puisieux, et al.
Pageof 6